Truist analyst Mark Hughes raised the firm’s price target on Aflac to $80 from $70 and keeps Hold rating on the shares after its Q2 earnings beat. The firm cites the management indicating that Japan’s recovery from the pandemic is a tailwind in the period even as Aflac continued its rollout of the new WINGS cancer product. Aflac shares are fairly valued at the high end of the Life group, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AFL:
- Early notable gainers among liquid option names on August 2nd
- Aflac price target raised to $86 from $79 at BofA
- Aflac Incorporated Announces Second Quarter Results, Reports Second Quarter Net Earnings of $1.6 Billion, Declares Third Quarter Cash Dividend
- Aflac reports Q2 adjusted EPS $1.58, consensus $1.43
- AFLAC Incorporated (AFL) Q2 Earnings Cheat Sheet
